Valuation: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Market Cap 23.94B 3.55B 3.07B 2.88B 2.62B 4.93B 340B 5B 33.84B 13.26B 170B 13.33B 13.04B 567B P/E 2024
10.7x
P/E 2025 16.5x
Enterprise Value 19.68B 2.92B 2.52B 2.37B 2.16B 4.05B 280B 4.11B 27.82B 10.9B 140B 10.96B 10.72B 466B EV / Sales 2024
2.3x
EV / Sales 2025 5.39x
Free-Float
31.71%
Yield 2024
4.16%
Yield 2025 10.5%
08-14 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-10 Tianjin Pharmaceutical Gets China Nod for Diabetes Combo Drug MT
08-10 Tianjin Pharmaceutical Signs 113-Million-Yuan Distribution Deal MT
08-09 Tianjin Pharmaceutical Unit Gets China's Nod for Diabetes Drug Registration MT
08-09 Tianjin Pharmaceutical Da Ren Tang to Sign Warehousing Deal MT
08-07 Xinxin Pharmaceutical Plant Receives Drug Registration Certificate for Saxagliptin and Metformin Hydrochloride Sustained-Release Tablets (I) CI
08-07 Tianjin Pharmaceutical Da Ren Tang Secures China Nod for Diabetes Combo Drug MT
07-14 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Six Months Ended 30 June 2026 CI
07-14 Tianjin Pharmaceuticals Warns of Up to 68% Plunge in H1 Profit MT
06-25 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Adjustments to the Composition of the Respective Board Committees CI
05-20 Chinese State-Backed Entities to Dispose of Stake in Tianjin Pharmaceutical Da Ren Tang Unit via Public Tender MT
05-15 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Appointment of Zhai Shuping as Independent and Non-Executive Director, Effective May 15, 2026 CI
05-15 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Liew Yoke Pheng Joseph as Independnet and Non-Executive Director, Chairman of the Audit Committee and A Member of the Remuneration Committee CI
1 day-0.83%
1 week-2.53%
Current month-6.35%
1 month-5.41%
3 months-15.62%
6 months-16.97%
Current year-21.39%
1 week 35.12
Extreme 35.12
37.14
1 month 35.12
Extreme 35.12
39.39
Current year 34.7
Extreme 34.7
48.2
1 year 34.7
Extreme 34.7
50.95
3 years 23.4
Extreme 23.4
50.97
5 years 17.98
Extreme 17.98
56.26
10 years 11.8
Extreme 11.8
56.26
Manager TitleAgeSince
Director of Finance/CFO 48 2023-07-20
Chief Tech/Sci/R&D Officer 56 2017-10-09
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 2024-11-25
Director/Board Member 56 2012-11-30
Director/Board Member 55 2021-12-09
Date Insider Type Main position Quantity % Market Cap.
1/8/20 Buy

Company Secretary

30,000 0.0053%
1/8/20 Buy

Chief Technology Officer

70,000 0.0124%
1/8/20 Buy 70,000 0.0124%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-2.53%-26.26%+3.70% 3.55B
-0.60%-2.62%-12.91%-6.04% 13.1B
-1.10%-2.89%-33.62%-57.05% 4.92B
-0.02%-3.97%+2.16%-0.35% 4.87B
-1.23%-0.41%+4.15%-26.61% 4.16B
+0.20%-0.90%-9.74%+15.54% 3.41B
-0.99%-6.39%-9.84%-8.50% 3.28B
-1.93%-0.06%-15.11%-15.88% 2.47B
-4.58%+6.02%-0.65%-10.37% 1.72B
-1.07%-1.64%-29.64%-13.30% 1.71B
Average -1.22%-1.94%-13.15%-11.88% 4.32B
Weighted average by Cap. -0.89%-1.99%-12.84%-11.89%

Financials

2024 2025
Net sales 7.31B 1.08B 936M 880M 800M 1.51B 104B 1.53B 10.33B 4.05B 51.92B 4.07B 3.98B 173B 4.92B 729M 630M 593M 539M 1.01B 69.87B 1.03B 6.95B 2.72B 34.94B 2.74B 2.68B 116B
Net income 2.23B 331M 286M 269M 244M 459M 31.67B 466M 3.15B 1.23B 15.84B 1.24B 1.21B 52.77B 2.13B 316M 273M 257M 233M 439M 30.28B 445M 3.01B 1.18B 15.14B 1.19B 1.16B 50.44B
Net Debt -3.91B -579M -500M -471M -428M -805M -55.5B -816M -5.52B -2.16B -27.76B -2.17B -2.13B -92.45B -4.26B -631M -545M -513M -466M -877M -60.48B -890M -6.02B -2.36B -30.25B -2.37B -2.32B -101B
Logo Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a China-based company principally engaged in the research, development, manufacturing and retail of Chinese herbal medicines, Chinese patent medicines, chemical raw materials and preparations, and nutritional health products. The Company operates its businesses through three segments. The Chinese Patent Medicine segment is mainly engaged in the research, development, manufacturing and sales of Chinese medicines, including Su Xiao Jiu Xin Pill, Jing Wan Hong Ruan Gao, An Gong Niu Huang Pill, Qing Gong Shou Tao Pill and other products. The Western Medicine segment is mainly engaged in the research, development, manufacturing and sales of Western medicines. The Others segment mainly includes economic information consulting services, house leasing and other businesses. The Company mainly operates its businesses in the domestic and overseas markets.
Employees
3,890
Date Price Change Volume
26-08-18 CN¥35.86 -0.83% 2,168,810
26-08-17 CN¥36.16 -0.03% 3,733,271
26-08-14 CN¥36.17 -1.69% 3,773,833
26-08-13 CN¥36.79 +0.19% 3,313,800
26-08-12 CN¥36.72 -0.19% 2,710,710

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 600329 Stock